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OBJECTIVES: To examine and compare costs and cost drivers for various meta-
static renal cell carcinoma (mRCC) drugs. METHODS: This retrospective cohort 
study used administrative healthcare claims from MarketScan® Commercial 
and Medicare Supplemental Databases to identify patients newly diagnosed 
with mRCC (index event) from 1/1/2006 to 3/31/2014, with continuous health 
plan enrollment at least 6 months prior to and 30 days following the index 
date. Treatment with approved mRCC products on or after the index date was 
required. Patients were followed until death, health plan enrollment end, ini-
tiation of non-mRCC chemotherapy, or study end. Healthcare costs reflect paid 
amounts to providers and out-of-pocket costs to patients. Bootstrapping was used 
to determine differences between costs of drugs. RESULTS: The study population 
included 3060 mRCC patients. Total per-patient-per-month costs for pazopanib 
($14,486) and sorafenib ($13,841) were not statistically lower at an alpha level of 
0.05 than sunitinib ($15,808). However, temsirolimus ($19,431) and IL-2 ($96,619) 
were significantly more costly than sunitinib. For inpatient and patient out-of-
pocket costs, IL-2 was significantly more costly than sunitinib. Outpatient costs 
of pazopanib and temsirolimus were both significantly more costly than suni-
tinib while sorafenib was significantly less costly. Multivariate modeling found 
that year of index date, number of metastatic sites, NCI comorbidity index score, 
and evidence of an adverse event during first line treatment were significantly 
associated with greater costs for all patients. In general, approximately 46% of 
total costs were specific to mRCC drug costs while 30% were due to inpatient 
stay. CONCLUSIONS: This study demonstrates that there may be significant cost 
differences between mRCC drugs and that mRCC drug costs represent the largest 
driver of total healthcare costs in this patient population. Further research on 
comparative effectiveness, weighing costs relative to clinical benefit, is needed.
PCN46
ChoiCe of SequeNtial BiologiCal theraPieS iN MetaStatiC ColoreCtal 
CaNCer (MCrC): a CoSt CoMPariSoN aNalySiS for Wild-tyPe KraS MCrC 
PatieNtS iN Brazil
Tsuchiya C.T., Kim H.S., La Scala C.S.
Roche Brazil, São Paulo, Brazil
OBJECTIVES: Colorectal cancer (CRC) is a major cause of morbidity and mortality 
worldwide. Approximately 25% of patients present metastatic disease at diagnosis 
and about 50% will develop metastatic disease. Patients with metastatic colorectal 
cancer (mCRC) and wild-type or mutated KRAS are eligible for sequential treat-
ments, including monoclonal antibodies as first or second-line regimens. Use of 
bevacizumab (Bev) through multiple lines (TML) may benefit patients with mCRC. 
Considering the emerging data, it is important to understand these implications 
in terms of costs for the Brazilian private healthcare system. Our objectives were 
to compare economic outcomes of different sequences of therapy including 
monoclonal antibodies for the treatment of mCRC. METHODS: Eight scenarios 
were analyzed, each one comparing different treatment sequences. A sequence 
of bevacizumab TML (first-line and beyond first progression) was compared in 
each scenario with another sequence without bevacizumab TML. To compare 
the economic outcomes, the monthly cost and the total cost of the sequence per 
patient were calculated, according to the first, second and third-lines combina-
tions. RESULTS: Considering a standard time of treatment of 12.8 months and 
progression-free survival (PFS) varying from 17.0 to 20.6, all scenarios with bevaci-
zumab TML were less costly than multiple lines without bevacizumab. The lowest 
monthly cost was related to bevacizumab TML (1stline bevacizumab 5mg+FOLFOX 
→ 2ndline bevacizumab 5mg+FOLFIRI → 3rdline best supportive care [BSC]). This 
sequence represents a monthly cost of R$ 18,192.41 per patient while the same 
scenario with cetuximab in first-line (1stline cetuximab 250mg+FOLFIRI → 2ndline 
bevacizumab 10mg+FOLFOX → 3rdline BSC) represents R$ 23,640.57 per month/
patient. CONCLUSIONS: Use of bevacizumab TML for mCRC is less costly compared 
with sequences of biological therapy that starts with cetuximab in the first-line fol-
lowed by bevacizumab in second-line treatment. Resource savings with sequential 
bevacizumab have the potential to optimize third-line treatment strategy for mCRC 
patients with wild-type KRAS in Brazil.
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OBJECTIVES: To investigate patterns of hemostat methods in surgeries and 
evaluate the healthcare resource utilization and economic burden of patients in 
China. METHODS: All Patients using oxidized regenerated cellulose (ORC), microfi-
brillar collagen hemostat (MCH), resorbable oxidized cellulose (ROC), and micropo-
rous polysaccharide hemispheres (MPH) after cholecystectomy, hysterectomy or 
other related surgeries in tertiary hospitals were identified from the 2012 dataset 
of the China Health Insurance Research Association (CHIRA) claims database which 
includes a nationwide, cross-sectional sampling of inpatients. Direct medical costs 
included diagnostic tests, surgery, physiotherapy, hemostat, medicines and consum-
ables cost. Descriptive statistics were used to describe patient profiles, healthcare 
resource utilization and direct medical cost. Two-tailed tests were performed at 95% 
confidence. Multiple linear regression (MLR) was used to identify main parameters 
that may influence inpatient costs thus providing patient selection criteria for a 
relative unbiased comparison. RESULTS: A total of 788 patients with the following 
characteristics, age, gender, surgery types, hemostats types, Length of Stay (LOS), 
Hospital tier were identified. Factors significantly impacted inpatient cost were 
Length of Stay, type of hemostat (ORC vs. others), tier of Medical Institute (MLR, 
p< 0.01). Among 382 patients who stayed at Tier 3 hospitals with LOS ≤ 14 days, the 
average inpatient costs of patients using ORC vs. other hemostats (MCH, ROC, MPH) 
were 21,101 RMB (±21,390), 23,246 RMB (±15,545), respectively. There was a signifi-
chronic pulmonary disease. The sunitinib cohort had less time between diagnosis and 
index prescription than the pazopanib cohort (334 vs. 422 days; p= 0.037). Proportions 
of patients with treatment continuation, discontinuation, switching, or interruption 
were NS different. Before imputation, adjusted mean [SD] daily medication costs dur-
ing persistence were higher for sunitinib ($218.19 [34.73] vs. $177.07 [45.76]; p< 0.0001), 
but NS different after imputation (sunitinib $181.41 [22.34] vs. pazopanib $175.77 
[44.26]; p= 0.213). Twelve-month adjusted RCC-related medical costs were signifi-
cantly lower for sunitinib than pazopanib before imputation ($36,638.96 [$25,199.38] 
vs. $45,219.75 [$34,828.70], p= 0.021) and after imputation ($36.393.90 [$26,543.89] vs. 
$45,652.99 [$35,226.83], p= 0.015. The RCC-related prescription costs were NS different 
between the two drugs before and after imputation. CONCLUSIONS: Treatment pat-
terns and persistence with sunitinib or pazopanib were NS different. Sunitinib daily 
cost was NS different from pazopanib after imputation. Further analysis is needed 
regarding dosing schedule, days supply, and related calculations.
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OBJECTIVES: The study aimed to (1) develop a cost model for colonoscopy prepa-
ration among patients referred for colonoscopy using split-dose reduced-volume 
oral sulfate solution (OSS) and generic polyethylene glycol with electrolytes solu-
tion (PEG-ELS), (2) examine cost-savings associated with OSS versus PEG-ELS, 
and (3) assess the robustness of the cost model. METHODS: Clinical efficacy of 
each agent was based on the results of a 541-patient clinical trial comparing OSS 
to PEG-ELS. Cleansing agent and colonoscopy procedure costs were calculated 
from OptumHealth Reporting & Insights claims data for 2010–Q12013. In the cost 
model, patients’ colonoscopies were tracked until the patient reached age 75. The 
difference per patient per year (PPPY) in total cleansing agent and colonoscopy 
procedure costs over the time horizon between the OSS and PEG-ELS cohort was 
calculated. One-way sensitivity analyses were also conducted to test the robust-
ness of the cost model. RESULTS: The cost model showed that OSS patients had 
fewer colonoscopies over the time horizon (OSS: 0.158 vs. PEG-ELS: 0.170 PPPY). 
Total PPPY costs were $280.34 for the OSS cohort and $296.36 for the PEG-ELS 
cohort, resulting in a cost-saving of $16.01 to the payer for the OSS cohort. Varying 
the annual colonoscopy completion rate, surveillance intervals, time horizon, and 
proportion of high risk patients did not change the observation of cost-savings 
under OSS. Cost-savings switched from the OSS to the PEG-ELS cohort in three 
cases: (1) base-case cost of a completed colonoscopy decreased by 75%, (2) base-
case cost of OSS increased to over $143 per usage, and (3) all non-completers 
were lost to follow up. CONCLUSIONS: From a payer’s perspective, the cost model 
showed that the use of OSS as the cleansing agent resulted in potential cost-
savings compared with PEG-ELS. The cost model was robust and cost-savings 
under OSS remained under various sensitivity analyses.
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OBJECTIVES: Cancer-related morbidity and mortality have dramatic impacts on 
patients and society. Most studies on the economic burden of cancer have focused 
on the direct costs attributed to healthcare expenditures or the indirect costs due 
to premature mortality. Cancer’s impact on absenteeism has been less well studied. 
The objective of this review was to summarize and characterize the literature on the 
economic impact of cancer-related absenteeism. METHODS: We searched PubMed for 
articles related to the costs of cancer-related absenteeism, which we defined as any 
type of workplace absence. Additional eligibility criteria included the evaluation of 
costs per patient and the presentation of absenteeism endpoints in monetary terms. 
Studies were characterized according to cancer type, healthcare setting (U.S., EU, Asia), 
valuation approaches, study time period, absenteeism endpoints, and cost results. 
All costs were adjusted to 2013 dollars or Euros using consumer price indexes and 
exchange rate data. RESULTS: We found 16 articles that met our inclusion criteria. 
Seven cancer or pre-cancer types were studied, with breast cancer (7 studies) and 
colorectal cancer (3 studies) being the most common. Absenteeism endpoints used 
by study authors varied considerably and included terms such as “absenteeism” (the 
actual term), “sick leave,” “short-term disability,” and “permanent disability (reduced 
hours or workforce departure).” For U.S. studies, total annual absenteeism costs per 
patient ranged from $3,235 (precancerous cervical lesions) to $59,241 (colorectal 
cancer). For European studies, total mean absenteeism costs per patient based on 
time until retirement age of 65 ranged from € 54,216 (breast cancer) to € 129,977 (colo-
rectal cancer). Overall, colorectal cancer was associated with the highest absentee-
ism costs. CONCLUSIONS: Based on the literature, it is apparent that cancer-related 
absenteeism poses a significant economic burden to patients, employers, and society. 
Additional research is required to better understand the absenteeism costs of various 
types of cancer and to make more accurate comparisons between them.
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